Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025
Benedetto Simone, Florian Lienert
Abstract
Older adults are at increased risk of severe chikungunya. Some countries advise against vaccinating ≥ 60 or ≥ 65-year-olds with the licenced live-attenuated vaccine (CHIKV LA, IXCHIQ), following severe adverse event (SAE) reports. A virus-like particle vaccine (CHIKV VLP, VIMKUNYA) is licensed in the United States (US), EU/EEA and the United Kingdom. Up to 31 August 2025, over 12,500 doses were administered in US and Germany; no SAEs in ≥ 65-year-olds were reported. Early post-authorisation data support its favourable safety profile in ≥ 65-year-olds.
Topics & Concepts
MedicineAdverse effectChikungunyaEnvironmental healthPublic healthChikungunya feverCoronavirus disease 2019 (COVID-19)Event (particle physics)Risk assessmentPediatricsVaccinationMEDLINEMedical emergency2019-20 coronavirus outbreakEmergency medicineVaccine safetyEpidemiologyPandemicAdverse Event Reporting SystemYoung adultPublic health surveillanceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyClinical trialMosquito-borne diseases and controlViral Infections and Outbreaks ResearchImmune responses and vaccinations